BSX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BS

Mkt Cap

$64.33B

Volume

10.65M

Next Earnings

October 28th

Loading chart

BS

BSXBoston Scientific Corp.

BSX

Pay with—

Available Balance0.00

BS

Mkt Cap

$63.97B

Volume

10.65M

Next Earnings

October 28th

Chart Financials Earnings News About Insider Filings

Boston Scientific (BSX) Rises Higher Than Market: Key FactsBoston Scientific (BSX) closed at $44.14, up 2.65% on the day but down 2.07% over the past month. The company is expected to report earnings on October 28, 2026, with projected EPS of $0.76 and revenue of $5.17 billion. Despite trading at a Forward P/E discount of 13.28 compared to its industry average of 19.61, BSX carries a Zacks Rank #4 (Sell) rating due to a 1.49% downward revision in consensus EPS projections over the past 30 days.Zacks Investment Research · Oct 15, 2026

Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance?Johnson & Johnson's shares fell 5.8% after Q3 2026 results showed earnings beat but sales missed expectations. MedTech segment underperformed with only 2.5% growth due to Abiomed declines and international market challenges, while Innovative Medicine remained strong. Despite headwinds, J&J raised full-year guidance and targets over $100 billion in 2026 revenue with accelerated growth expected in 2027.Zacks Investment Research · Oct 14, 2026

Why Boston Scientific (BSX) Outpaced the Stock Market TodayBoston Scientific (BSX) closed at $42.73, up 1.64% on the day, outperforming the S&P 500. The company is expected to report earnings on October 28, 2026, with predicted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY). However, BSX holds a Zacks Rank #4 (Sell) rating due to a 1.3% decline in consensus EPS estimates over the past month. The stock trades at a Forward P/E of 12.92, below its industry average, but faces headwinds despite valuation appeal.Zacks Investment Research · Oct 9, 2026

China Adult Feeding Tubes and Formula Market Outlook to 2033 - Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion OpportunitiesResearchAndMarkets.com released a comprehensive market report on China's adult feeding tubes and formula market through 2033, providing revenue, volume, and pricing forecasts. The report analyzes two main segments (Adult Feeding Tubes and Adult Feeding Formula) and includes competitive landscape data with 2025 company share information for key market participants.GlobeNewswire Inc. · Oct 9, 2026

Boston Scientific (BSX) Advances While Market Declines: Some Information for InvestorsBoston Scientific (BSX) gained 1.11% on October 8, 2026, outperforming the broader market decline. The medical device manufacturer is expected to report Q3 earnings on October 28 with forecasted EPS of $0.76 (+1.33% YoY) and revenue of $5.17 billion (+2.12% YoY). However, the stock has declined 7.52% over the past month and holds a Zacks Rank of #4 (Sell) following a 1.3% decrease in consensus EPS estimates over the last 30 days. The stock trades at a Forward P/E of 12.78, below its industry average of 19.24.Zacks Investment Research · Oct 8, 2026

Boston Scientific Corporation (BSX) is Attracting Investor Attention: Here is What You Should KnowBoston Scientific (BSX) has attracted investor attention but faces near-term headwinds. The stock declined 7.5% over the past month, underperforming the S&P 500's +1.4% gain. While the company demonstrated strong recent earnings and revenue surprises, earnings estimate revisions have been negative over the past month. The stock received a Zacks Rank #4 (Sell) rating, suggesting potential underperformance in the near term, though it trades at a valuation discount to peers.Zacks Investment Research · Oct 8, 2026

Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsightThe global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.GlobeNewswire Inc. · Oct 6, 2026

Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?Johnson & Johnson's MedTech segment experienced mixed results in Q2 2026, with growth slowing due to weaker Cardiovascular sales and declining Abiomed procedures, though Shockwave showed strong double-digit growth. The company expects improvement in H2 2026 driven by Vision, Orthopedics, and Surgery segments, but faces ongoing headwinds from China's VBP program and competitive pressures.Zacks Investment Research · Oct 6, 2026

Boston Scientific (BSX) Stock Sinks As Market Gains: What You Should KnowBoston Scientific (BSX) declined 1.46% to $42.60, underperforming the broader market which gained 0.73%. The stock has lost 7.92% over the past month. While analysts expect modest earnings growth of 1.33% YoY and revenue growth of 3.25% for the upcoming quarter, the company received a Zacks Rank #4 (Sell) rating due to a 1.3% downward revision in consensus EPS estimates over the last 30 days. However, the stock trades at a discount with a Forward P/E of 13.28 versus the industry average of 19.67.Zacks Investment Research · Oct 2, 2026

Can ISRG Offset China Weakness With Expansion in India and Japan?Intuitive Surgical faces headwinds in China due to weak tenders, domestic competition, and pricing pressure, with only two systems placed. However, the company is diversifying growth through strong momentum in India following da Vinci 5 clearance and improved conditions in Japan with new reimbursement policies supporting 25 system placements. International da Vinci procedures grew 20% in Q2, with management maintaining its 2026 procedure growth outlook of 13.5-15.5%.Zacks Investment Research · Oct 2, 2026

to start trading

BS

BSXBoston Scientific Corp.

BSX

Pay with—

Available Balance0.00

Your PositionYou don't own any BSX yet.

Related Tickers

Earnings